However, due to the side effects of commercially available VEGF-reducing drugs, they can be ruled out as a suitable treatment for OHSS; therefore, researchers are looking for new medications to treat OHSS. The gene discussed is VEGFA; the disease is ovarian hyperstimulation syndrome.